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Abstract
Background: Loss to follow-up (LTFU) is common in antiretroviral therapy (ART) programmes. Mortality is a competing risk
(CR) for LTFU; however, it is often overlooked in cohort analyses. We examined how the CR of death affected LTFU estimates
in Zambia and Switzerland.
Methods and Findings: HIV-infected patients aged $18 years who started ART 2004–2008 in observational cohorts in
Zambia and Switzerland were included. We compared standard Kaplan-Meier curves with CR cumulative incidence. We
calculated hazard ratios for LTFU across CD4 cell count strata using cause-specific Cox models, or Fine and Gray
subdistribution models, adjusting for age, gender, body mass index and clinical stage. 89,339 patients from Zambia and
1,860 patients from Switzerland were included. 12,237 patients (13.7%) in Zambia and 129 patients (6.9%) in Switzerland
were LTFU and 8,498 (9.5%) and 29 patients (1.6%), respectively, died. In Zambia, the probability of LTFU was overestimated
in Kaplan-Meier curves: estimates at 3.5 years were 29.3% for patients starting ART with CD4 cells ,100 cells/ml and 15.4%
among patients starting with $350 cells/mL. The estimates from CR cumulative incidence were 22.9% and 13.6%,
respectively. Little difference was found between naı¨ve and CR analyses in Switzerland since only few patients died. The
results from Cox and Fine and Gray models were similar: in Zambia the risk of loss to follow-up and death increased with
decreasing CD4 counts at the start of ART, whereas in Switzerland there was a trend in the opposite direction, with patients
with higher CD4 cell counts more likely to be lost to follow-up.
Conclusions: In ART programmes in low-income settings the competing risk of death can substantially bias standard
analyses of LTFU. The CD4 cell count and other prognostic factors may be differentially associated with LTFU in low-income
and high-income settings.
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Introduction
In most settings, regular attendance at health facilities is critical
to the comprehensive medical care of HIV-infected patients.
During these visits, health care workers examine patients for
clinical progression, provide and monitor combination antiretro-
viral therapy (ART), and counsel them on minimizing the risk of
HIV transmission. Despite this need for regular monitoring,
significant loss to follow-up has been demonstrated in ART
programmes and cohort studies – both in industrialized and
resource-limited settings – at rates often exceeding reported
mortality [1]. In a collaborative analysis of patients who had been
on ART for six months in Europe and North America, 27% were
lost to follow-up over a median of 3.75 years [2]. In the Swiss HIV
Cohort Study (SHCS) loss to follow-up was 121 per 1000 patient
years in the pre ART era [3], but decreased in the ART era to
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33.6 per 1000 patient years [4]. In industrialized settings less
advanced disease, younger age, injection drug use and homeless-
ness have been associated with loss to follow-up [5–7].
Loss to follow-up is more common in resource-poor settings. In
an Antiretroviral Treatment in Lower Income Countries (ART-
LINC) study, loss to follow-up after 1 year was above 40% in some
programs [8], and associated with more advanced clinical disease
and lower CD4 cell counts. Similarly, an analysis of the large ART
programme jointly administered by the Zambian Ministry of
Health and the Centre for Infectious Disease Research in Zambia
(CIDRZ) showed that predictors of treatment failure or death also
predicted loss to follow-up [9]. A meta-analysis of studies that
traced patients lost to follow-up to ascertain their vital status
showed that in sub-Saharan Africa 40% of those traced had died
[10]. High rates of loss to follow-up may affect mortality estimates
in ART programmes if patients lost to follow-up have a different
prognosis compared to similar patients remaining in care [11].
Obtaining valid estimates of loss to follow-up at different points in
time is therefore important when evaluating ART programmes.
Death is a competing risk of loss to follow-up: patients who die
can no longer become lost to follow-up. Competing risks are defined
as events that prevent the outcome of interest from occurring. They
are common in longitudinal studies and are particularly important
in populations at high risk of death [12,13]. For example, death
from all causes is a competing risk when studying recurrences after
treatment of cancer, and death from other causes is a competing risk
when studying a specific cause of death. In standard Kaplan-Meier
analyses, the follow-up of those developing a competing event is
simply censored, assuming that the probability of the outcome of
interest is the same as that of comparable patients remaining under
observation. However, this assumption is invalid because the
outcome of interest can no longer occur in those developing the
competing event, and such analyses will therefore overestimate the
probability of the outcome of interest. This situation can be seen as
an extreme form of ‘informative’ censoring, where censoring is
associated with the probability of the outcome [14]. Analyses that
ignore competing events are however regularly published [7,15,16]
even though they may produce misleading results.
We examined how the competing risk of death affected
estimates of loss to follow-up in cohorts of patients starting ART
in Zambia and Switzerland.
Methods
We analysed data from two well-described HIV cohorts: a
Zambian cohort supported by the Centre for Infectious Disease
Research in Zambia (CIDRZ) and the Zambian Ministry of
Health [9,17] (referred to hereafter as the CIDRZ cohort) and the
Swiss HIV Cohort Study [4].
CIDRZ cohort, Zambia
CIDRZ-supported activities in HIV care and treatment began in
2004 across four sites in Lusaka. Since then, the programme has
expanded to 68 facilities, most of them government health centres
and hospitals. Across all sites, clinical care is standardized according
to the Zambian National HIV guidelines [18]. Over the analysis
period, individuals were eligible for ART when: (a) they were
diagnosed with a stage IV conditions according to World Health
Organization (WHO) criteria; (b) their CD4 cell count was below
200 cells/mL; or (c) they had a stage III condition and their CD4 was
between 200 and 350 cells/mL. Clinical and immunologic
monitoring occurred every 3–6 months. Although viral load testing
is available, its use is limited for reasons of cost and operational
constraints [19], particularly outside of Lusaka. Patients with missed
visits are contacted by community health workers and reminded
about their appointments [20]. All patient-level data are entered
into a comprehensive electronic medical record supported by the
Ministry of Health. Additional details of the CIDRZ programme
can be found elsewhere [9,17]. Approval for use of these
programmatic data was obtained from the University of Zambia
Research Ethics Committee (Lusaka, Zambia) and the University of
Alabama at Birmingham (Birmingham, AL, USA). Only routine
clinical data were analyzed for the present study and informed
consent from patients was not obtained.
Swiss HIV Cohort Study, Switzerland
Established in 1988, the Swiss HIV Cohort Study (SHCS) is a
national prospective cohort study of HIV-infected patients followed
up at outpatient departments of five University hospitals (Basel,
Berne, Geneva, Lausanne and Zurich) and two Cantonal hospitals
(Lugano and St. Gallen). A comparison with official AIDS
notifications and deaths indicated that about 70% of all patients
living with AIDS in Switzerland participate in the study [21]. Data
collection and study procedures are standardised. Detailed
information on demographics, mode of HIV acquisition, risk
behaviours, clinical events, laboratory results (i.e. viral load, CD4
cell counts and additional data), and treatments is collected at
registration and then at 6-monthly intervals. Clinical AIDS
diagnoses (Center for Disease Control and Prevention [CDC] stage
C) are recorded by the treating physician on the basis of the revised
2008 CDC criteria [22]. All services including ART and laboratory
testing are covered by compulsory health insurance. Patients who
do not attend the next follow-up visit are actively traced. Further
details about the SHCS programme is provided elsewhere [4].
Local ethics committees at all seven SHCS sites approved the study
and written informed consent was obtained from all participants.
Eligibility criteria and definitions
Treatment-naı¨ve patients aged 18 years or older who started
ART between 2004 and 2008 were eligible for the present
analysis. ART was defined as a combination of at least three
antiretroviral drugs from at least two classes. The clinical stage of
disease was classified as less advanced (CDC stage A/B, WHO
stage I/II) or advanced (CDC stage C, WHO stage III/IV).
Patients were grouped according to their CD4 cell count (,100;
100–199; 200–349; $350 cells/mL) and body mass index (BMI;
,20; 20–25; .25 kg/m2) at the start of ART.
Outcomes
Two endpoints were considered: loss-to follow up, and death as
a competing event. Patients were considered lost to follow-up if
they were not seen for more than 14 months, irrespective of
whether or not they came back later on. These patients were
censored at their last visit, or the last visit before the gap in follow-
up. In Zambia, empirical work suggested that the optimal
definition for loss to follow-up was 60 days since the last missed
clinic appointment [23]; however, because this was not appropri-
ate for the Swiss cohort, we used 14 months as the threshold for
both cohorts. Patients who were transferred out to another site
were also censored at their last visit. We used an ‘‘intent-to-
continue-treatment’’ approach and thus ignored subsequent
changes to treatment, including interruptions and terminations.
Statistical analyses
We first compared the ‘naı¨ve’ Kaplan-Meier analyses to
competing risk cumulative incidence curves using the Aalen-
Johansen estimator [24]. Individuals contributed person-time from
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the start of ART until the last follow-up visit or known date of
death. We then compared cause-specific hazard ratios from Cox
models across baseline CD4 groups with the subdistribution
hazard ratios from the model described by Fine and Gray [13,25–
27]. In the Cox model observations with failures from other causes
(death or loss to follow-up respectively in this study) are censored.
The Cox model is a reasonable choice but is restricted to
modelling instantaneous risk functions [28]. The Fine and Gray
model makes use of the subdistribution hazard to model
cumulative incidence and thus quantify the overall benefit or
harm of an exposure [28]. Patients with the competing event were
kept at risk and continued to contribute person time, with the
remaining time at risk weighted by the inverse probability of
censoring [25]. Analyses were adjusted for age, sex and categories
of CD4 cell count, BMI, and clinical stage at start of ART. In
CIDRZ weight and height was sometimes not measured on the
day of starting ART and therefore the last value before starting
ART was carried forward. Partial residual analysis and model-
based diagnostics were used to test the assumption of proportional
hazards in all models. Data were analysed using SAS version 9.2
(SAS Institute Inc., Cary, NC, USA) and R version 2.13.1 (www.r-
project.org).
Results
Patient characteristics
In the CIDRZ cohort, 89,339 patients were followed for a
total of 124,163 person-years. The median observation time was
10.0 months (interquartile range [IQR] 1.8–23.4 months). All
patients were presumed to have been infected through
heterosexual contacts, although these data are not routinely
collected. The number of patients starting ART increased
rapidly from 5,667 in 2004 to 25,772 in 2008. A median of
1,188 patients (range: 139–2,173 patients) started ART at each
site and 6,988 patients (7.8%) were known to have been
transferred to another facility.
In the SHCS 1,860 patients were followed for 3,989 person-
years, including 755 patients (40.6%) infected through sex between
men, 852 patients (45.8%) infected heterosexually, 196 patients
(10.5%) infected through intravenous drug use and 57 patients
(3.1%) infected through an unknown source. The median
observation time was 33.7 months (IQR 24.1–39.0). The number
of patients starting ART remained stable over time with a range of
372 to 439 patients starting each year. The median number of
patients per site was 230 (range 45–725) and 19 (1.02%) were
transferred out to another site.
Table 1 shows the characteristics of the patients at start of ART.
The patients in CIDRZ were younger, more likely to be female,
and more likely to present at an advanced disease stage. The most
commonly prescribed ART regimens varied substantially between
the two cohorts. In the SHCS 19.7% of patients used a protease
inhibitor-based regimen (mostly lamivudine [3TC], zidovudine
[AZT], and lopinavir [LPV]). In Zambia, most patients started
ART with a NNRTI-based regimen: 41.7% initiated a combina-
tion of stavudine (d4T), 3TC, and nevirapine (NVP), while 21.1%
initiated a combination of AZT, 3TC, and NVP.
Table 1. Baseline characteristics and mortality at end of follow-up among patients starting antiretroviral therapy in two cohorts in
Zambia and Switzerland.
Zambia (CIDRZ) Switzerland (SHCS)
N Median or % IQR N Median or % IQR
Total No. of patients 89,339 100% 1,860 100%
CD4 cell count (cells/mL) 82,955 147 74–240 1,860 322 164–491
Age (years) 89,339 35 30–42 1,860 38 32–45
Body mass index (kg/m2) 89,233 19.7 17.7–22.1 1,860 23.6 21.5–26.1
Sex
Women 54,432 60.9% 592 31.8%
Men 34,907 39.1% 1,268 68.2%
Advanced clinical stage*
Women 35,476 65.1% 115 30.1%
Men 25,821 73.9% 477 32.2%
Most common treatment regimens
d4T/3TC, NVP 37,254 41.7%
AZT/3TC, NVP 18,850 21.1%
AZT/3TC, EFV 166 8.9%
ETC, TNV, EFV 12,060 13.5%
AZT/3TC, LPV 367 19.7%
ETC, TNV, LPV 190 10.2%
Mortality
Women 4,512 8.3% 10 1.7%
Men 3,986 11.5% 29 2.2%
CIDRZ: Centre for Infectious Disease Research in Zambia; SHCS: Swiss HIV Cohort Study; IQR: interquartile range; d4T: stavudine; 3TC: lamivudine; NVP: nevirapine; AZT:
zidovudine; EFV: efavirenz; ETC: emtricitabine; TNV: tenofovir; LPV: lopinavir.
*Advanced: WHO stage III/IV or CDC clinical stage C.
doi:10.1371/journal.pone.0027919.t001
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Comparison of Kaplan-Meier and competing risk
cumulative incidence
Figure 1 shows the naı¨ve Kaplan-Meier curves and the
competing risk cumulative incidence. In the naı¨ve Kaplan-Meier
analysis the proportion of patients lost to follow-up after 3.5 years
in the CIDRZ cohort was 29.3% among patients starting ART
with CD4 cell counts ,100 cells/mL and 15.4% among patients
starting ART with counts $350 cells/mL. When the competing
risk of death was taken into account, estimates of loss to follow-up
were lower: 22.9% for ART patients with CD4 counts,100 cells/
mL at treatment initiation and 13.6% for ART patients with CD4
counts $350 cells/mL at treatment initiation. In patients starting
with CD4 counts ,100 cells/mL the estimated risk of death at 3.5
years was 19.9% in the KM analysis and 16.3% in the competing
risk analysis. In patients with CD4 counts $350 cells/mL it was
8.8% and 6.3% respectively. In the SHCS, the results from the
Kaplan-Meier analysis and the competing risk approaches were
similar irrespective of baseline CD4 cell count, both for loss to
follow-up and for mortality. Mortality was below 10% at 3.5 years
in both CD4 cell strata and the influence of the competing risk was
negligible.
Rates, cause-specific hazard ratios and subdistribution
hazard ratios
Rates of loss to follow-up declined in Zambia from 211.6 per
1,000 person-years in the first 6 months of ART to 53.5 per 1,000
person-years thereafter. The corresponding rates of death were
174.3 and 26.3 per 1,000 person-years. In the SHCS loss to follow-
up declined from 31.8 to 26.8 per 1,000 person-years and death
rates from 17.5 to 7.4 per 1,000 person-years in the same period.
Table 2 shows the results from the standard Cox models for
mortality and loss to follow-up and the competing risk subdis-
tribution model for loss to follow-up for different CD4 strata. The
results from the two models were consistent. In Zambia the risk of
loss to follow-up and death increased with decreasing CD4 counts
at the start of ART. In Switzerland there was a trend in the
opposite direction, with patients with higher CD4 cell counts more
likely to be lost to follow-up. The cause-specific hazard ratios for
death also increased with decreasing CD4 cell count but the
association was somewhat weaker than in Zambia and not
statistically significant. Finally, the hazard ratios comparing
Switzerland with Zambia were below 1 for all CD4 strata, with
slightly lower cause-specific hazard ratios, particularly at lower
CD4 cell counts (Table 3).
Discussion
We compared outcomes in ART programme from Zambia and
Switzerland to illustrate the importance of death as a competing
risk when estimating loss to follow-up. Standard Kaplan-Meier
analyses that ignored the competing risk of death substantially
overestimated the cumulative incidence of loss to follow-up in
patients starting with low CD4 counts in Zambia. In contrast,
there was little bias among populations experiencing lower
mortality, including patients starting ART with high CD4 counts
in Zambia and all patients in Switzerland. The results from the
cause-specific Cox models and the more complex Fine and Gray
model were comparable, both when analyzing the effect of CD4
count strata on the rate of loss to follow-up, and when comparing
the Swiss with the Zambian cohort.
Figure 1. Standard Kaplan-Meier (KM) curves and cumulative incidence curves from competing risk (CR) analyses of loss to follow-
up and death in the CIDRZ cohort in Zambia and the Swiss HIV Cohort Study.
doi:10.1371/journal.pone.0027919.g001
The Competing Risk of Loss to Follow-Up and Death
PLoS ONE | www.plosone.org 4 December 2011 | Volume 6 | Issue 12 | e27919
We estimated the cumulative incidence of developing the event
of interest (i.e., loss to follow-up) in the presence of a competing
risk (i.e., death). The cumulative incidence represents the
probability that an individual will experience an event of interest
by time (t). In contrast to the standard Kaplan-Meier approach,
the cumulative incidence from the competing risk analysis depends
not only on the number of patients who experienced an event, but
also on the number of patients who did not experience a
competing event. Similarly, we used two approaches to model the
effect of covariates in the present of the competing risk. The cause-
specific Cox model, in which competing causes are censored, is a
reasonable and practical choice but is restricted to modelling
instantaneous risk functions [28–30]. The Fine and Gray model
makes use of the subdistribution hazard to model cumulative
incidence and thus quantify the overall benefit or harm of an
exposure, however, it is considerably more complex [25,28]. Of
note, the effect of a covariate on cumulative incidence will also
depend on its effect on the competing risk. In other words, the
effect of a covariate on the cause-specific hazard may be different
from the corresponding effect on cumulative incidence [12,13].
This was recently illustrated using the example of the competing
risks of stopping first line ART or switching to second-line ART
[28].
Competing risk analyses are still rare in the literature, compared
to standard survival analyses. In September 2011, MEDLINE
Table 2. Unadjusted and adjusted hazard ratios across categories of baseline CD4 cell count in Zambia and Switzerland.
CD4 cell count Subdistribution model Cause-specific Cox model
(cells/mL) Loss to follow-up Loss to follow-up Death
sHR 95% CI P HR 95% CI P HR 95% CI P
Zambia
Crude analysis ,0.0001 ,0.0001 ,0.0001
,100 1.76 1.64–1.89 1.92 1.79–2.06 2.94 2.66–3.26
100–199 1.15 1.06–1.24 1.17 1.08–1.26 1.52 1.36–1.69
200–349 1.07 0.99–1.16 1.08 1.00–1.17 1.10 0.98–1.23
$350 1 1 1
Adjusted analysis* ,0.0001 ,0.0001 ,0.0001
,100 1.66 1.54–1.77 1.84 1.71–1.97 2.69 2.43–2.97
100–199 1.16 1.08–1.25 1.19 1.11–1.29 1.58 1.42–1.76
200–349 1.07 0.99–1.16 1.08 1.00–1.17 1.12 0.99–1.25
$350 1 1 1
Switzerland
Crude analysis 0.38 0.40 0.37
,100 0.61 0.33–1.13 0.62 0.33–1.15 2.59 0.81–8.28
100–199 0.92 0.54–1.55 0.94 0.55–1.59 2.04 0.63–6.64
200–349 0.98 0.61–1.57 0.98 0.61–1.58 1.50 0.47–4.79
$350 1 1 1
Adjusted analysis* 0.24 0.24 0.71
,100 0.57 0.30–1.11 0.57 0.30–1.12 1.96 0.58–6.63
100–199 1.02 0.60–1.73 1.03 0.61–1.76 1.70 0.52–5.55
200–349 1.07 0.66–1.73 1.07 0.66–1.74 1.36 0.42–4.35
$350 1 1 1
Results for loss to follow-up from the subdistribution competing risk model and for loss to follow-up and death from standard Cox models are shown.
HR: hazard ratio; sHR: subdistribution hazard ratio; CI: confidence interval.
*Adjusted for age, gender, disease stage and body mass index.
doi:10.1371/journal.pone.0027919.t002
Table 3. Unadjusted and adjusted hazard ratios for loss to
follow-up from competing risk models and cause-specific Cox
models comparing the Swiss HIV Cohort Study with the CIDRZ
cohort in Zambia.
Subdistribution model Cause-specific Cox model
sHR 95% CI P HR 95% CI P
Crude ,0.0001 ,0.0001
,100 0.31 0.26–0.38 0.27 0.23–0.33
100–199 0.48 0.40–0.58 0.44 0.37–0.54
200–349 0.51 0.43–0.62 0.48 0.40–0.58
$350 0.55 0.45–0.67 0.52 0.43–0.63
Adjusted* ,0.0001 ,0.0001
,100 0.30 0.18–0.48 0.24 0.16–0.42
100–199 0.67 0.46–0.97 0.64 0.44–0.93
200–349 0.69 0.51–0.93 0.68 0.51–0.92
$350 0.76 0.52–1.12 0.75 0.51–1.10
HR: hazard ratio; sHR: subdistribution hazard ratio; CI: confidence interval.
*Adjusted for age, gender, disease stage and body mass index.
doi:10.1371/journal.pone.0027919.t003
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returned only 85 hits when searching titles and abstracts with free
text words ‘‘competing risk analysis’’ or ‘‘competing risk analyses’’,
with about half of articles from oncology. In contrast, repeating the
search with words ‘‘Kaplan-Meier’’ or ‘‘Cox regression’’ returned
thousands of hits. A possible explanation for the poor adoption of
competing risk modelling in medical research is the lack of
dedicated routines in commonly used statistical software. This is
now changing with routines available in several packages, such as
in R and Stata version 11.
An important strength of our study was the analysis of a
combined dataset, which allowed using the same definitions and
coding of variables in the Zambian and Swiss cohorts. We could
thus examine the risk of loss to follow-up and death across the
same CD4 categories, while adjusting for a common set of
confounding variables. The CIDRZ programme is typical of many
sites involved in the scale-up of ART in resource-limited settings.
The scale-up follows a public health approach and must cope with
the realities of constrained health systems, including health care
worker shortages and limited diagnostic capacity for co-morbid-
ities and co-infections. Key program characteristics include the
standardisation of first-line and second-line regimens, simplified
clinical decision-making, and standardised clinical and laboratory
monitoring [31]. The choice of regimens is determined primarily
by cost and can include drugs that are no longer widely used in
industrialized countries. In Switzerland, by contrast, doctors
prescribe from the full range of available antiretroviral drugs,
resistance testing is used to individually tailor drug regimens, and
CD4 cell counts and viral load are monitored frequently [32].
We found that the determinants of loss to follow-up differed in
Zambia and Switzerland. In the African setting, sicker patients
were more likely to be lost to follow-up, confirming previous
studies from resource-limited settings [33,34]. In Switzerland,
there was a (statistically non-significant) trend in the opposite
direction, in line with results from the French Hospital Database
on HIV, which found that a history of an AIDS-defining illness
was associated with reduced loss to follow-up [35], and the UK
CHIC [36] and Hospital of Bergamo cohorts [37] where loss to
follow-up was associated with a higher CD4 cell count.
We sought to illustrate the importance of competing risks when
investigating the association between CD4 cell counts and loss to
follow-up in Zambia and Switzerland. For example, we did not
consider the different transmission groups in the SHCS but previous
analyses showed that loss to follow-up was more common among
current intravenous drug users (IDUs) compared to former IDUs
and other risk groups [38]. Patients lost to follow-up are
systematically traced in the SHCS to ascertain outcomes, but are
not consistently traced in the CIDRZ cohort. Even when program
resources are available, a significant proportion of patients cannot be
contacted [20]. Reasons for follow-up losses are thus often unknown.
Similarly, causes of deaths are not routinely collected in the CIDRZ
cohort and no national death registries exist in Zambia to
supplement this information. Furthermore, we used an intention-
to-treat approach and thus ignored subsequent changes to treatment,
including interruptions and terminations. An alternative approach
would have been to account for treatment changes and time varying
covariates by the use of inverse probability of treatment and
censoring weights as in Cole et al [29]. Since drug interruptions and
reasons for interruptions are not recorded systematically in the
CIDRZ cohort we could not, however, use this approach.
The results obtained for mortality also deserve comment. It is
important to note that cumulative mortality estimates from both
the competing risk analysis and the Kaplan-Meier analysis may
not be representative of all patients starting ART in the CIDRZ
cohort (Figure 1). The competing risk analysis relates to patients
remaining in care and thus estimates mortality during follow-up
only: mortality in patients lost to follow up is not considered. The
Kaplan-Meier method assumes that those lost to follow-up
experience the same mortality as comparable patients remaining
in care, ignoring the fact that in resource-limited settings mortality
among patients lost is substantially higher than among patients
remaining in care. In other words, censoring is highly ‘‘informa-
tive’’ [10]. Several methods have been proposed to correct for the
under ascertainment of mortality due to loss to follow-up in these
settings, including double sampling techniques, multiple imputa-
tions and nomogram-based adjustments [11,33,39]. In Switzer-
land the situation is different: loss to follow-up mainly reflects
unknown transfers to other care givers, and deaths are ascertained
by tracing patients and linking the data to routine mortality files.
In conclusion, our results demonstrate that death should be
considered as a competing risk when estimating the cumulative
incidence and determinants of loss to follow-up in settings where
mortality is high. Continued efforts are needed to minimize loss to
follow-up to improve patient outcomes in resource-limited settings.
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